Detalhe da pesquisa
1.
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.
Cancer
; 130(8): 1234-1245, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38127487
2.
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Gynecol Oncol
; 172: 82-91, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37001446
3.
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
Gynecol Oncol
; 162(2): 375-381, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34112513
4.
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
Future Oncol
; 17(26): 3433-3443, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34409858